Colesevelam Hydrochloride + Ezetimibe + Simvastatin

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia

Conditions

Hypercholesterolemia

Trial Timeline

Mar 1, 2005 → Oct 1, 2005

About Colesevelam Hydrochloride + Ezetimibe + Simvastatin

Colesevelam Hydrochloride + Ezetimibe + Simvastatin is a approved stage product being developed by Daiichi Sankyo for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00185107. Target conditions include Hypercholesterolemia.

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00185107ApprovedCompleted

Competing Products

20 competing products in Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Evacetrapib + Ezetimibe + Atorvastatin + PlaceboEli LillyPhase 3
32
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
43
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
43
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
43
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
43
colesevelam HCl + placeboDaiichi SankyoApproved
43
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
30
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
26
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
43
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
atrovastatinAstellas PharmaPre-clinical
26
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
43
PPAR alpha + atorvastatin + placeboEli LillyPhase 2
35
Evacetrapib + PlaceboEli LillyPhase 3
32
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
35
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40